Cover - shares |
3 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Feb. 09, 2026 |
|
| Cover [Abstract] | ||
| Document Type | 10-Q/A | |
| Amendment Flag | true | |
| Amendment Description | As previously disclosed in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on May 6, 2026, on April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors of the Company (the “Board”) terminated the employment of the Company’s former Chief Executive Officer (“CEO”) for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between the Company and its former CEO, as amended and restated), effective immediately for, among other things, conduct that the Special Committee believed was inconsistent with Company policy. As a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the “Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025. Accordingly, the Company’s internal control over financial reporting as of December 31, 2025, as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 (the “Original Form 10-Q”) were not effective. In addition, the Company’s disclosure controls and procedures were not effective as of December 31, 2025, due to the material weakness in internal control over financial reporting as described above. The reassessment of the effectiveness of the Company’s disclosure controls and procedures and its internal control over financial reporting described above did not result in any misstatement in the Company’s previously issued condensed consolidated interim financial statements for the quarterly period ended December 31, 2025. As a result, the Company is not restating its condensed consolidated interim financial statements in this Amendment No. 1 (this “Amendment”) to the Original Form 10-Q. The Company is filing this Amendment to amend the following: ●Item 4. “Controls and Procedures” was amended to reflect ineffective disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 as a result of the material weakness related to entity-level control deficiencies as described in the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, (the “2025 Form 10-K/A”) filed with the SEC on August 28, 2026. ●Item 6. “Exhibits” of the Original Form 10-Q is amended and restated to reflect the new certifications referenced below. This Amendment also includes the following exhibits to replace exhibits previously filed: ● new currently dated certifications (as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended), by the Company’s principal executive officer and principal financial officer. Except as described in this Explanatory Note, this Amendment does not amend, modify or update disclosures included in the Original Form 10-Q, nor does it reflect events occurring after the filing of the Original Form 10-Q. Among other things, business-related disclosures, risk factors and forward-looking statements made in the Original Form 10-Q have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Form 10-Q, and any such statements should be read in their historical context. Accordingly, this Amendment should be read in conjunction with the Company’s filings with the SEC that were made subsequent to the filing of the Original Form 10-Q and this Amendment. | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Dec. 31, 2025 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2026 | |
| Current Fiscal Year End Date | --09-30 | |
| Entity File Number | 001-37606 | |
| Entity Registrant Name | ANAVEX LIFE SCIENCES CORP. | |
| Entity Central Index Key | 0001314052 | |
| Entity Tax Identification Number | 98-0608404 | |
| Entity Incorporation, State or Country Code | NV | |
| Entity Address, Address Line One | 630 5th Avenue | |
| Entity Address, Address Line Two | 20th Floor | |
| Entity Address, City or Town | New York | |
| Entity Address, State or Province | NY | |
| Entity Address, Country | US | |
| Entity Address, Postal Zip Code | 10111 | |
| City Area Code | 844 | |
| Local Phone Number | 689-3939 | |
| Title of 12(b) Security | Common Stock Par Value $0.001 | |
| Trading Symbol | AVXL | |
| Security Exchange Name | NASDAQ | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Large Accelerated Filer | |
| Entity Small Business | false | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 92,671,758 |